Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Acute myeloid leukemia |
2件: PML, RARA | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
2 | Adherens junction |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
3 | Adipocytokine signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
4 | African trypanosomiasis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
5 | AGE-RAGE signaling pathway in diabetic complications |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
6 | Allograft rejection |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
7 | Alzheimer disease |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
8 | Amoebiasis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
9 | AMPK signaling pathway |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
10 | Amyotrophic lateral sclerosis (ALS) |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
11 | Antifolate resistance |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
1件: TYMS | D01223 | Capecitabine | 1件: 94 | ||
12 | Antigen processing and presentation |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
13 | Apoptosis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
14 | Asthma |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
15 | Bile secretion |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1件: NR1H4 | D00734 | Ursodeoxycholic acid | 12件: 6, 8, 20, 67, 84, 93, 94, 95, 96, 97, 234, 299 | ||
16 | Bladder cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
17 | Breast cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
18 | C-type lectin receptor signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
19 | Calcium signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
20 | cAMP signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
21 | Central carbon metabolism in cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
22 | Chagas disease (American trypanosomiasis) |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
23 | Chemokine signaling pathway |
2件: CCR2, CCR5 | D09878 | Cenicriviroc | 1件: 94 |
24 | Choline metabolism in cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
25 | Colorectal cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
26 | Cushing syndrome |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
27 | Cytokine-cytokine receptor interaction |
2件: CCR2, CCR5 | D09878 | Cenicriviroc | 1件: 94 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
28 | Dilated cardiomyopathy (DCM) |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
29 | Drug metabolism - other enzymes |
1件: HPRT1 | D00161 | Mercaptopurine | 5件: 86, 94, 96, 97, 164 |
D04931 | |||||
2件: IMPDH1, IMPDH2 | D01392 | Mizoribine | 8件: 46, 49, 51, 53, 66, 94, 222, 224 | ||
1件: RRM1 | D01370 | Cladribine | 2件: 13, 94 | ||
30 | EGFR tyrosine kinase inhibitor resistance |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
31 | Endocrine resistance |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
32 | Endocytosis |
1件: CCR5 | D09878 | Cenicriviroc | 1件: 94 |
1件: EGFR | D04023 | Erlotinib | 1件: 94 | ||
D07907 | |||||
1件: PML | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 | ||
33 | Endometrial cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
34 | Epithelial cell signaling in Helicobacter pylori infection |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
35 | Epstein-Barr virus infection |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
36 | ErbB signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
37 | Estrogen signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: RARA | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 | ||
38 | Fc epsilon RI signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
39 | Fluid shear stress and atherosclerosis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
40 | Focal adhesion |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
41 | FoxO signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
42 | Gap junction |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
43 | Gastric cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: RARB | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 | ||
44 | Glioma |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
45 | Glucagon signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
46 | Glutathione metabolism |
1件: RRM1 | D01370 | Cladribine | 2件: 13, 94 |
47 | GnRH signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
48 | Graft-versus-host disease |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
49 | Hematopoietic cell lineage |
1件: MS4A1 | D02994 | Rituximab | 42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
50 | Hepatitis B |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
51 | Hepatitis C |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 | ||
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
52 | Hepatocellular carcinoma |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
53 | Herpes simplex virus 1 infection |
1件: PML | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
54 | HIF-1 signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
55 | Human cytomegalovirus infection |
1件: CCR5 | D09878 | Cenicriviroc | 1件: 94 |
1件: EGFR | D04023 | Erlotinib | 1件: 94 | ||
D07907 | |||||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
56 | Human immunodeficiency virus 1 infection |
1件: CCR5 | D09878 | Cenicriviroc | 1件: 94 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
57 | Human papillomavirus infection |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
58 | Human T-cell leukemia virus 1 infection |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
59 | Hypertrophic cardiomyopathy (HCM) |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
60 | IL-17 signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
61 | Inflammatory bowel disease (IBD) |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
62 | Influenza A |
1件: PML | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
63 | Insulin resistance |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
64 | JAK-STAT signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
65 | Kaposi sarcoma-associated herpesvirus infection |
1件: CCR5 | D09878 | Cenicriviroc | 1件: 94 |
66 | Legionellosis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
67 | Leishmaniasis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
68 | Malaria |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
69 | MAPK signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
70 | Melanoma |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
71 | Metabolic pathways |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1件: HPRT1 | D00161 | Mercaptopurine | 5件: 86, 94, 96, 97, 164 | ||
D04931 | |||||
2件: IMPDH1, IMPDH2 | D01392 | Mizoribine | 8件: 46, 49, 51, 53, 66, 94, 222, 224 | ||
1件: RRM1 | D01370 | Cladribine | 2件: 13, 94 | ||
1件: TYMS | D01223 | Capecitabine | 1件: 94 | ||
72 | MicroRNAs in cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
73 | mTOR signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
74 | Natural killer cell mediated cytotoxicity |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
75 | Necroptosis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
76 | Neuroactive ligand-receptor interaction |
1件: NR3C1 | D00246 | Budesonide | 10件: 66, 85, 93, 94, 95, 96, 97, 98, 228, 299 |
77 | NF-kappa B signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
78 | NOD-like receptor signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
79 | Non-alcoholic fatty liver disease (NAFLD) |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
80 | Non-small cell lung cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: RARB | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 | ||
81 | One carbon pool by folate |
1件: TYMS | D01223 | Capecitabine | 1件: 94 |
82 | Osteoclast differentiation |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
83 | Oxytocin signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
84 | Pancreatic cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
85 | Parathyroid hormone synthesis, secretion and action |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
86 | Pathogenic Escherichia coli infection |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
87 | Pathways in cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
3件: PML, RARA, RARB | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 | ||
88 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
89 | Pertussis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
90 | Phospholipase D signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
91 | PI3K-Akt signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
92 | PPAR signaling pathway |
1件: PPARA | D01366 | Bezafibrate | 5件: 20, 93, 94, 160, 316 |
D00565 | Fenofibrate | 5件: 8, 79, 93, 94, 265 | |||
93 | Prostate cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
94 | Proteoglycans in cancer |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
95 | Purine metabolism |
1件: HPRT1 | D00161 | Mercaptopurine | 5件: 86, 94, 96, 97, 164 |
D04931 | |||||
2件: IMPDH1, IMPDH2 | D01392 | Mizoribine | 8件: 46, 49, 51, 53, 66, 94, 222, 224 | ||
1件: RRM1 | D01370 | Cladribine | 2件: 13, 94 | ||
96 | Pyrimidine metabolism |
1件: RRM1 | D01370 | Cladribine | 2件: 13, 94 |
1件: TYMS | D01223 | Capecitabine | 1件: 94 | ||
97 | Rap1 signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
98 | Ras signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
99 | Regulation of actin cytoskeleton |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
100 | Relaxin signaling pathway |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
101 | Rheumatoid arthritis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
102 | RIG-I-like receptor signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
103 | Shigellosis |
1件: EGFR | D04023 | Erlotinib | 1件: 94 |
D07907 | |||||
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
104 | Small cell lung cancer |
1件: RARB | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
105 | Sphingolipid signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
106 | Systemic lupus erythematosus |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
107 | T cell receptor signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
108 | Terpenoid backbone biosynthesis |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
109 | TGF-beta signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
110 | Th17 cell differentiation |
1件: RARA | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
111 | TNF signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
112 | Toll-like receptor signaling pathway |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
113 | Toxoplasmosis |
1件: CCR5 | D09878 | Cenicriviroc | 1件: 94 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
114 | Transcriptional misregulation in cancer |
2件: PML, RARA | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
115 | Tuberculosis |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
116 | Type I diabetes mellitus |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
117 | Type II diabetes mellitus |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
118 | Ubiquitin mediated proteolysis |
1件: PML | D00094 | Tretinoin | 5件: 2, 63, 75, 94, 231 |
119 | Viral carcinogenesis |
1件: CCR5 | D09878 | Cenicriviroc | 1件: 94 |
120 | Viral protein interaction with cytokine and cytokine receptor |
2件: CCR2, CCR5 | D09878 | Cenicriviroc | 1件: 94 |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
121 | Yersinia infection |
1件: TNF | D00754 | Thalidomide | 18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |